2026 ASH®
Annual Meeting & Exposition December 12-15, 2026 ▪ New Orleans, Louisiana

Paper Details

Abstracts, authors, affiliations, and disclosures.

Sunday, December 13, 2026
06:00 p.m. - 08:00 p.m.
MCCNO - Hall F
Access, Representation, Population Health, Technology and Procedures, Assays, Molecular Testing, Emerging Technologies, Treatment Considerations, Combination Therapy, Supportive Care, Therapy Sequence, Biological Therapies, Transplantation, Non-Biological Therapies, Chemotherapy, Palliative Care, Adverse Events, Artificial Intelligence (AI), Deep Learning, Generative AI, Machine Learning, Biological Processes, Pathogenesis, Genomics, Molecular Biology, Clinical Practice (Health Services and Quality), Clinical Guidelines, Health Economics, Practice Models, Quality of Care, Systems-Based Hematology, Diseases, Infectious Diseases, Bacterial, Lymphoid Malignancies, Myeloid Malignancies, Acute Myeloid Malignancies, Chronic Myeloid Malignancies, Measurable Residual Disease, Research, AML, Translational Research, MDS, Clinical Research, Clinical Trials, Epidemiology, Health Outcomes Research, Health Disparities Research, Patient-Reported Outcomes, Real-World Evidence, Survivorship, Study Population, Human, Adult, Elderly, Pediatric, Young Adult
PAPER

3383 Clonal dynamics of post-transplant relapse of monoallelic vs. multi-hit TP53-mutant myelodysplastic neoplasms and acute myeloid leukemia

Shyam A Patel, MD, PhD, Laurie K Pearson, MD2, Mara Epstein, ScD3, Kevin O'Sullivan, MD4, Robert Yuan, MD5, David Cachia, MD6, Tina Zhang, MD7, Talha Badar, MD8, Jonathan Gerber, MD9, Matthew Epstein10, Salwa Khedr, MD11, Lloyd Hutchinson, PhD12, Patricia Miron, PhD13, Anne Higgins, PhD14, Jan Cerny, MD, PhD15
1 UMass Chan Medical School, Worcester, Massachusetts, United States
2 UMass Chan Medical School, Worcester, Massachusetts, United States
3 UMass Chan Medical School, Worcester, Massachusetts, United States
4 UMass Chan Medical School, Worcester, Massachusetts, United States
5 UMass Chan Medical School, Worcester, Massachusetts, United States
6 UMass Chan Medical School, Worcester, Massachusetts, United States
7 UMass Chan Medical School, Worcester, Massachusetts, United States
8 Mayo Clinic, Jacksonville, Florida, United States
9 UMass Chan Medical School, Worcester, Massachusetts, United States
10 UMass Chan Medical School, Worcester, Massachusetts, United States
11 UMass Chan Medical School, Worcester, Massachusetts, United States
12 UMass Chan Medical School, Worcester, Massachusetts, United States
13 UMass Chan Medical School, Worcester, Massachusetts, United States
14 UMass Chan Medical School, Worcester, Massachusetts, United States
15 UMass Chan Medical School, Worcester, Massachusetts, United States

Background: Decisions about hematopoietic cell transplantation (HCT) candidacy for patients with TP53-mutant myelodysplastic neoplasms (MDS) and acute myeloid leukemia (AML) remain highly challenging, as long-term remissions are rare. Mortality within the one-year post-HCT period is often due to early relapse. In many cases, relapse develops prior to the onset of substantial graft-versus-leukemia effect, negating the effect of the allograft against TP53-mutant cells. Such concepts have led to hesitancy among physicians offering potentially curative HCT, especially given the regulatory requirement for reporting of one-year survival metrics. A pressing need remains the determination of which patients derive the most benefit from HCT. We have previously modeled clonal dynamics TP53-mutant MDS/AML, but we now aim to perform dedicated post-HCT analysis with the goal of understanding the impact of allelic state on relapse patterns.

Methods: A total of 174 patients with MDS or AML with TP53 disruption were identified between 2011 and 2026 from Hematopathology records. Among these, 34 (19.5%) underwent HCT. Median age of HCT recipients was 65.4 ± 11.9 years. Twenty-seven (79.4%) of 34 HCT recipients underwent serial next-generation sequencing pre- and post-HCT for clonal tracking. Among these 27 patients, 9 (33.3%) had monoallelic TP53 and 18 (66.7%) had multi-hit TP53, based on the strict definition per Table 21 of the International Consensus Classification: two or more TP53 mutations with VAF ≥10%; or a single TP53 mutation plus loss of chromosome 17p, copy-neutral loss of heterozygosity, complex karyotype, or TP53 variant allele frequency (VAF) >50%. Among the 18 HCT recipients with multi-hit TP53, 17 (94.4%) had complex karyotype and 8 (44.4%) had TP53 VAF >50%. Clonal tracking was performed by adjusting VAF for copy number variation (CNV) (gain or loss) from serial bone marrow aspirates, as previously described (Patel SA et al., 2023). CNV estimation used an algorithm that estimated the tumor percentage based on the concept that the probe signal could not be fewer than zero copies, and CNV was performed on sequencing data for samples harboring 20% or higher tumor load.

Results: Median overall survival (mOS) was significantly longer in patients who underwent HCT (n = 34) compared to those who did not undergo HCT (n = 140) (440 days vs. 162 days, p = 0.0015). One-year post-HCT mortality was 48.1% for the overall cohort, 55.6% for the monoallelic TP53 cohort, and 44.4% for the multi-hit TP53 cohort. Post-HCT clonal dynamic modeling showed that 100% of HCT recipients with monoallelic TP53 had clearance of TP53 mutation post-HCT, while only 23 (67.6%) of 34 HCT recipients with multi-hit TP53 had clearance of TP53 mutation post-HCT. Resurgence or persistence of TP53 mutation post-HCT was found exclusively in patients with multi-hit TP53. Post-HCT mOS (from Day 0) for monoallelic TP53 vs. multi-hit TP53 was 363 days vs. 224 days (p = 0.12). Among HCT recipients with monoallelic TP53, most (53.8%) died from non-relapse mortality, whereas among HCT recipients with multi-hit TP53, most (66.7%) died of progressive disease. Median time to engraftment was similar between monoallelic and multi-hit TP53 (20.0 ± 3.8 days vs. 20.0 ± 5.3 days, p = 0.96). Rates of acute graft-versus-host disease were also similar (40.0% vs. 42.1%).

Conclusions: Although patients with monoallelic vs. multi-hit TP53 experienced similar post-HCT survival, they demonstrated distinct mechanisms of death within the first year. Clearance of TP53 mutations predominated in the monoallelic TP53 cohort, whereas persistence or re-emergence of TP53 mutations predominated in the multi-hit TP53 cohort. Post-HCT trajectories in the multi-hit TP53 cohort were characterized by unmeasurable residual disease in the immediate post-HCT period, followed by overt relapse. Results from the monoallelic TP53 cohort are consistent with prior observations that true monoallelic disease, particularly in the absence of complex karyotype, may reflect a more favorable disease biology. These data suggest that consideration of TP53 allelic state may be a crucial factor when deciding whether to offer HCT on an individualized basis. These illustrations provide insight into the behavior of TP53-mutant clones subject to the stress of HCT and support the concept that therapeutic interventions are needed to specifically prevent post-HCT relapse of multi-hit TP53.

Shyam A Patel, MD, PhD: Taiho - Consultancy (Includes expert testimony); Syndax - Consultancy (Includes expert testimony); Geron - Consultancy (Includes expert testimony); Bristol Myers Squibb - Consultancy (Includes expert testimony)